Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CSChampions Oncology, Inc. logo

Champions Oncology, Inc. (CSBR)

NASDAQ Capital Market · Currency in USD
$4.72 ▼ -0.04 (-0.84%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$4.76
Open
$4.65
Day's Range
$4.64 – $4.78
52 Week Range
$4.59 – $8.31
Volume
3,676
Avg. Volume
10,046
Market Cap
$65.70M
Beta (5Y Monthly)
0.44
PE Ratio (TTM)
--
EPS (TTM)
-$0.08
Earnings Date
Dec 15, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$12.00

Profile: Champions Oncology, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
214
CEO
Robert Brainin

Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle.

Earnings

Next report: Tue, Dec 15, 2026
EPS estimate $0.02 · Revenue est. $16.37M
DateEst.Actual
Sep 10, 2026-$0.01$0.05Beat
Jul 27, 2026-$0.05$0.01Beat
Mar 12, 2026$0.09-$0.02Miss
Dec 15, 2025$0.08$0.02Miss
Sep 15, 2025-$0.01-$0.03Miss
Jul 23, 2025-$0.20-$0.13Beat

Analyst view

Consensus price target
$12.00 ▲ +154.2%
Range $12.00 – $12.00
Rating: Buy
Buy 71% · Hold 29% · Sell 0%

Get free alerts on CSBR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.